THE EVALUATION OF THE CONNECTION BETWEEN MOTOR PERFORMANCE SKILLS AND BODY COMPOSITION OF THE GIRLS

The Purpose: This study was done for evaluating the connection between motor performance skills and body composition of the girls between 6-10 ages. The Method: 57 schoolgirls between 6-10 ages were included to the study. Weight, Age, Height, Body Mass Index (BMI), Free Fat Mass (FFM), Lean Muscle Mass (LMM), Body Fat Mass (BFM) and Body Fat Percentage (BFP) values were measured with (Inbody 230) branded tanita. Long jump, right hand and left hand strength, back strength, 20 meters speed test, sit & reach test, 1 minute pull-up and flamingo balance tests were applied to the participants. Results: Pearson Correlation Test was applied for the analysis by using SPSS 23.0 program. According to the results, the average age is (8,00±,926) years, the average height is (128,7±6,64) cm and the average weight is (28,6±6,67) kg. There is a statistically meaningful relation between long jump, right hand, left hand, back strength, flamingo balance test and BFM, FFM, LMM, BMI and BFP at the (p<0.01) level. However, there is no relation found between 20 meters speed test, sit & reach test, 1 minute pull-up test and body composition parameters. Discussion and Conclusion: At the end of our study, we can say that there is a meaningful relation in a positive way between some motor performance skills and body composition of the girls.  Article visualizations

Sarcopenic obesity is not associated with sexual dysfunction in older adults: a cross-sectional study

AbstractBackground This study aimed to investigate the frequency of sexual dysfunction (SD) and the association between SD and body composition abnormalities, such as sarcopenia, obesity, and sarcopenic obesity.Methods Older adults (≥65 years) were included. Sarcopenic obesity was diagnosed by using newly defined ESPEN-EASO diagram. Sarcopenia was diagnosed according to the European Working Group on Sarcopenia in Older People criteria. Obesity was defined using the fat percentile cut-offs suggested by ESPEN-EASO. SD was determined by Arizona Sexual Experience Scale (ASEX).Results Two-hundred and sixty-seven volunteers (64.4% female, mean age 73.63 ± 6.22 years) participated in this study. One-hundred seventy-eight individuals (66.7%) had SD. It was present in 83.1% and 36.8% of the females and males, respectively (p < 0.0001). There was no association between SD and sarcopenia alone (OR: 1.359, 95% CI: 0.650–2.838, p = 0.415) or obesity alone (OR: 0.986, 95% CI: 0.543–1.791, p = 0.963). Sarcopenic obesity was significantly associated with SD (OR: 9.116, 95% CI: 1.173–70.851, p = 0.035). However, this significance was lost after the model was adjusted for gender, marital status, and comorbidities (OR: 4.676, 95% CI: 0.578–37.801, p = 0.148).Conclusions SD was present in 66.7% of the older adults and was not associated with sarcopenia, obesity, or sarcopenic obesity. Further longitudinal studies are needed on this topic

Pulmonary hypertension classification based on machine learning using standart chest X-Ray: ATA Artificial Intelligence Study-1

[No Abstract Available

Azalmış ejeksiyon fraksiyonu olan kalp yetersizliği hastalarında anjiyotensin reseptörü neprilysin inhibitörü: Türkiye’den gerçek dünya deneyimi (ARNi-TR)

Objective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angio tensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey.Methods: The ARNi-TR is a multicenter, nonintervention al, retrospective, observational study. Overall, 779 patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were examined. Initial clinical status, biochemical and echocardiographic parameters, and New York Heart Association functional class (NYHA-FC) values were compared with follow-up values after 1 year of ARNi use. In addition, the effect of ARNi on number of annual hospitalizations was investigated, and the patients were divided into 2 groups, depending on whether ARNi was ini tiated at hospitalization or under outpatient clinic control.Results: N-terminal pro-brain natriuretic peptide (NT-proB NP), left-ventricle ejection fraction (LV-EF), and NYHA-FC values improved significantly in both groups (all parame ters, p<0.001) within 1-year follow-up. In both groups, a de crease in hemoglobin A1c (HbA1c) values was observed in ARNi use (p<0.001), and a decrease in daily diuretic doses and hospitalizations owing to HF were observed after ARNi use (all comparisons, p<0.001). Hypotension (16.9%) was the most common side effect in patients using ARNi.Conclusion: The ARNi-TR study offers comprehensive re al-life data for patients using ARNi in Turkey. The use of ARNi has shown significant improvements in FC, NT-proB NP, HbA1c levels, and LV-EF. Likewise, reductions in the number of annual hospitalizations and daily furosemide doses for HF were seen in this study

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.

Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and >= 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET